Technical Outlook And Game Plan For CRISPR Therapeutics AG (NASDAQ: CRSP)

CRISPR Therapeutics AG (CRSP) concluded trading on Wednesday at a closing price of $43.30, with 4.23 million shares of worth about $183.11 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -7.70% during that period and on February 12, 2025 the price saw a gain of about 9.29%. Currently the company’s common shares owned by public are about 85.74M shares, out of which, 81.60M shares are available for trading.

Stock saw a price change of 2.56% in past 5 days and over the past one month there was a price change of 11.45%. Year-to-date (YTD), CRSP shares are showing a performance of 10.01% which decreased to -38.15% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $36.52 but also hit the highest price of $91.10 during that period. The average intraday trading volume for CRISPR Therapeutics AG shares is 1.91 million. The stock is currently trading 4.70% above its 20-day simple moving average (SMA20), while that difference is up 0.71% for SMA50 and it goes to -12.70% lower than SMA200.

CRISPR Therapeutics AG (NASDAQ: CRSP) currently have 85.74M outstanding shares and institutions hold larger chunk of about 65.42% of that.

The stock has a current market capitalization of $3.70B and its 3Y-monthly beta is at 1.78. It has posted earnings per share of -$4.36 in the same period. It has Quick Ratio of 22.07 while making debt-to-equity ratio of 0.12. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CRSP, volatility over the week remained 5.39% while standing at 4.86% over the month.

Stock’s fiscal year EPS is expected to drop by -12.75% while it is estimated to increase by 27.20% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by TD Cowen on Feb-13-25 offering a Hold rating for the stock and assigned a target price of $35 to it. Coverage by H.C. Wainwright stated CRISPR Therapeutics AG (CRSP) stock as a Buy in their note to investors on February 03, 2025, suggesting a price target of $65 for the stock. On August 06, 2024, Needham Reiterated their recommendations, while on August 02, 2024, Rodman & Renshaw Initiated their ratings for the stock with a price target of $90. Stock get a Neutral rating from Guggenheim on June 28, 2024.

Most Popular

Related Posts